Dr. David A Braun delved into detail on the molecular factors driving exceptional responses to immunotherapy in metastatic ...

Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

The study emphasizes the need for further research to make exceptional responses more common in RCC treatment. In patients with RCC, exceptional response to immunotherapy may be related to clonal ...

The median progression-free survival was 30.3 months, and the median overall survival was not reached. The combination of belzutifan and cabozantinib has demonstrated “promising” antitumor ...

The development of specific angiogenesis inhibitors has drastically improved renal cancer treatment in recent years. Currently, four VEGF receptor inhibitors (sorafenib, sunitinib, pazopanib and ...